J&J dumps Hanmi obesity drug following midphase trials

Johnson & Johnson has returned the rights to HM12525A to Hanmi Pharmaceutical after getting a look at data from an obesity trial. The decision is another blow for Hanmi, which lost a $690 million deal with Eil Lilly in January and will now forego up to $810 million in milestones from J&J.